Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.3 EX-3.3
- 3.4 EX-3.4
- 10.55 EX-10.55
- 10.56 EX-10.56
- 10.57 EX-10.57
- 10.58 EX-10.58
- 23.1 EX-23.1
- 23.2 EX-23.2
- 99.5 EX-99.5
- 99.6 EX-99.6
- 99.7 EX-99.7
- 99.8 EX-99.8
- 99.9 EX-99.9
- EX-FILING FEES Calculation of Filing Fee Tables
- Download Excel data file
- View Excel data file
Associated filings
- 14 Feb 24 424B3 Prospectus supplement
- 14 Feb 24 EFFECT Notice of effectiveness
- 1 Feb 24 UPLOAD Letter from SEC
- 16 Jan 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
14 Nov 23 S-4 Registration of securities issued in business combination transactions
SER similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-4/S-1 of our report dated March 31, 2023 (which includes an explanatory paragraph relating to AgeX Therapeutics, Inc.’s ability to continue as a going concern), relating to the consolidated financial statements of AgeX Therapeutics, Inc., which is contained in such Registration Statement. We also consent to the reference to our Firm under the caption “Experts” in such Registration Statement.
/s/ WithumSmith+Brown, PC
San Francisco, California
November 14, 2023